DNA topoisomerases as targets of anticancer drugs

H. F. Shang, T. L. Chen, C. P. Lin, J. Hwang

Research output: Contribution to journalArticle

Abstract

Eukaryotic DNA topoisomerases are ubiquitous nuclear enzymes that alter DNA topology by breaking and rejoining DNA strands. There are two classes of DNA topoisomerases; DNA topoisomerase I introduces a transient single-strand DNA break, while topoisomerase II introduces transient double-strand DNA breaks for each catalytic reaction. Both are important for solving topological problems arising during DNA replication, transcription, recombination and other cellular functions. Recently, scientists have realized the importance of topoisomerases as new therapeutic targets for antibacterial, antifungal, antiparasitic, antiviral and anticancer drugs. The present review focuses on anticancer drugs targeting mammalian DNA topoisomerases, which are named DNA topoisomerase poison. Camptothecin and VM26 (teniposide) are representative DNA topoisomerase poisons that target DNA topoisomerase I and topoisomerase II, respectively. These drugs alter the breakage-reunion reactions of DNA topoisomerases by trapping topoisomerase-DNA cleavable complexes in both the purified system and cultured cells. However, resistance to various DNA topoisomerase poisons has been documented in cancer cells with repect to MDR1 overexpression, reduced topoisomerase levels, drug-resistant mutant topoisomerase, lengthened cell cycle time and altered DNA repair function. A better understanding of the molecular targets for anticancer drugs and the various drug-resistance mechanisms may help us to discover and tailor new drugs for particular drug-resistant tumors.

Original languageEnglish
Pages (from-to)145-153
Number of pages9
JournalJournal of Food and Drug Analysis
Volume3
Issue number3
Publication statusPublished - 1995

Fingerprint

DNA Topoisomerases
DNA topoisomerase
Type I DNA Topoisomerase
antineoplastic agents
Poisons
Pharmaceutical Preparations
Type II DNA Topoisomerase
DNA topoisomerase (ATP-hydrolysing)
Reunion
Teniposide
Antiparasitic Agents
Single-Stranded DNA Breaks
DNA
Camptothecin
Double-Stranded DNA Breaks
drugs
Drug Delivery Systems
DNA Replication
Drug Resistance
DNA Repair

Keywords

  • DNA topoisomerase I
  • DNA topoisomerase II
  • DNA topoisomerase poison

ASJC Scopus subject areas

  • Food Science
  • Pharmacology

Cite this

Shang, H. F., Chen, T. L., Lin, C. P., & Hwang, J. (1995). DNA topoisomerases as targets of anticancer drugs. Journal of Food and Drug Analysis, 3(3), 145-153.

DNA topoisomerases as targets of anticancer drugs. / Shang, H. F.; Chen, T. L.; Lin, C. P.; Hwang, J.

In: Journal of Food and Drug Analysis, Vol. 3, No. 3, 1995, p. 145-153.

Research output: Contribution to journalArticle

Shang, HF, Chen, TL, Lin, CP & Hwang, J 1995, 'DNA topoisomerases as targets of anticancer drugs', Journal of Food and Drug Analysis, vol. 3, no. 3, pp. 145-153.
Shang HF, Chen TL, Lin CP, Hwang J. DNA topoisomerases as targets of anticancer drugs. Journal of Food and Drug Analysis. 1995;3(3):145-153.
Shang, H. F. ; Chen, T. L. ; Lin, C. P. ; Hwang, J. / DNA topoisomerases as targets of anticancer drugs. In: Journal of Food and Drug Analysis. 1995 ; Vol. 3, No. 3. pp. 145-153.
@article{10bc065170914e0691afaaa977898bfa,
title = "DNA topoisomerases as targets of anticancer drugs",
abstract = "Eukaryotic DNA topoisomerases are ubiquitous nuclear enzymes that alter DNA topology by breaking and rejoining DNA strands. There are two classes of DNA topoisomerases; DNA topoisomerase I introduces a transient single-strand DNA break, while topoisomerase II introduces transient double-strand DNA breaks for each catalytic reaction. Both are important for solving topological problems arising during DNA replication, transcription, recombination and other cellular functions. Recently, scientists have realized the importance of topoisomerases as new therapeutic targets for antibacterial, antifungal, antiparasitic, antiviral and anticancer drugs. The present review focuses on anticancer drugs targeting mammalian DNA topoisomerases, which are named DNA topoisomerase poison. Camptothecin and VM26 (teniposide) are representative DNA topoisomerase poisons that target DNA topoisomerase I and topoisomerase II, respectively. These drugs alter the breakage-reunion reactions of DNA topoisomerases by trapping topoisomerase-DNA cleavable complexes in both the purified system and cultured cells. However, resistance to various DNA topoisomerase poisons has been documented in cancer cells with repect to MDR1 overexpression, reduced topoisomerase levels, drug-resistant mutant topoisomerase, lengthened cell cycle time and altered DNA repair function. A better understanding of the molecular targets for anticancer drugs and the various drug-resistance mechanisms may help us to discover and tailor new drugs for particular drug-resistant tumors.",
keywords = "DNA topoisomerase I, DNA topoisomerase II, DNA topoisomerase poison",
author = "Shang, {H. F.} and Chen, {T. L.} and Lin, {C. P.} and J. Hwang",
year = "1995",
language = "English",
volume = "3",
pages = "145--153",
journal = "Journal of Food and Drug Analysis",
issn = "1021-9498",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - DNA topoisomerases as targets of anticancer drugs

AU - Shang, H. F.

AU - Chen, T. L.

AU - Lin, C. P.

AU - Hwang, J.

PY - 1995

Y1 - 1995

N2 - Eukaryotic DNA topoisomerases are ubiquitous nuclear enzymes that alter DNA topology by breaking and rejoining DNA strands. There are two classes of DNA topoisomerases; DNA topoisomerase I introduces a transient single-strand DNA break, while topoisomerase II introduces transient double-strand DNA breaks for each catalytic reaction. Both are important for solving topological problems arising during DNA replication, transcription, recombination and other cellular functions. Recently, scientists have realized the importance of topoisomerases as new therapeutic targets for antibacterial, antifungal, antiparasitic, antiviral and anticancer drugs. The present review focuses on anticancer drugs targeting mammalian DNA topoisomerases, which are named DNA topoisomerase poison. Camptothecin and VM26 (teniposide) are representative DNA topoisomerase poisons that target DNA topoisomerase I and topoisomerase II, respectively. These drugs alter the breakage-reunion reactions of DNA topoisomerases by trapping topoisomerase-DNA cleavable complexes in both the purified system and cultured cells. However, resistance to various DNA topoisomerase poisons has been documented in cancer cells with repect to MDR1 overexpression, reduced topoisomerase levels, drug-resistant mutant topoisomerase, lengthened cell cycle time and altered DNA repair function. A better understanding of the molecular targets for anticancer drugs and the various drug-resistance mechanisms may help us to discover and tailor new drugs for particular drug-resistant tumors.

AB - Eukaryotic DNA topoisomerases are ubiquitous nuclear enzymes that alter DNA topology by breaking and rejoining DNA strands. There are two classes of DNA topoisomerases; DNA topoisomerase I introduces a transient single-strand DNA break, while topoisomerase II introduces transient double-strand DNA breaks for each catalytic reaction. Both are important for solving topological problems arising during DNA replication, transcription, recombination and other cellular functions. Recently, scientists have realized the importance of topoisomerases as new therapeutic targets for antibacterial, antifungal, antiparasitic, antiviral and anticancer drugs. The present review focuses on anticancer drugs targeting mammalian DNA topoisomerases, which are named DNA topoisomerase poison. Camptothecin and VM26 (teniposide) are representative DNA topoisomerase poisons that target DNA topoisomerase I and topoisomerase II, respectively. These drugs alter the breakage-reunion reactions of DNA topoisomerases by trapping topoisomerase-DNA cleavable complexes in both the purified system and cultured cells. However, resistance to various DNA topoisomerase poisons has been documented in cancer cells with repect to MDR1 overexpression, reduced topoisomerase levels, drug-resistant mutant topoisomerase, lengthened cell cycle time and altered DNA repair function. A better understanding of the molecular targets for anticancer drugs and the various drug-resistance mechanisms may help us to discover and tailor new drugs for particular drug-resistant tumors.

KW - DNA topoisomerase I

KW - DNA topoisomerase II

KW - DNA topoisomerase poison

UR - http://www.scopus.com/inward/record.url?scp=0028892230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028892230&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028892230

VL - 3

SP - 145

EP - 153

JO - Journal of Food and Drug Analysis

JF - Journal of Food and Drug Analysis

SN - 1021-9498

IS - 3

ER -